Paediatric Low-grade Glioma: the Role of Classical Pathology in Integrated Diagnostic Practice
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Low-grade gliomas are a cause of severe and often life-long disability in children. Pathology plays a key role in their management by establishing the diagnosis, excluding malignant alternatives, predicting outcomes and identifying targetable genetic alterations. Molecular diagnosis has reshaped the terrain of pathology, raising the question of what part traditional histology plays. In this review, we consider the classification and pathological diagnosis of low-grade gliomas and glioneuronal tumours in children by traditional histopathology enhanced by the opportunities afforded by access to comprehensive genetic and epigenetic characterisation.
References
1.
Bailey S, Davidson A, Parkes J, Tabori U, Figaji A, Epari S
. How Can Genomic Innovations in Pediatric Brain Tumors Transform Outcomes in Low- and Middle-Income Countries?. JCO Glob Oncol. 2022; 8:e2200156.
PMC: 9812475.
DOI: 10.1200/GO.22.00156.
View
2.
Bandopadhayay P, Ramkissoon L, Jain P, Bergthold G, Wala J, Zeid R
. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016; 48(3):273-82.
PMC: 4767685.
DOI: 10.1038/ng.3500.
View
3.
Jansen A, Belousova E, Benedik M, Carter T, Cottin V, Curatolo P
. Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study. Front Neurol. 2019; 10:821.
PMC: 6688052.
DOI: 10.3389/fneur.2019.00821.
View
4.
Fernandez C, Figarella-Branger D, Girard N, Bouvier-Labit C, Gouvernet J, Paz Paredes A
. Pilocytic astrocytomas in children: prognostic factors--a retrospective study of 80 cases. Neurosurgery. 2003; 53(3):544-53; discussion 554-5.
DOI: 10.1227/01.neu.0000079330.01541.6e.
View
5.
Capper D, Stichel D, Sahm F, Jones D, Schrimpf D, Sill M
. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018; 136(2):181-210.
PMC: 6060790.
DOI: 10.1007/s00401-018-1879-y.
View